Traditional herbal medicine combined with first-line platinum-based chemotherapy for advanced non-small-cell lung cancer
Open Access
- 17 September 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (37) , e27163
Abstract
Background: Non-small-cell lung cancer (NSCLC) is a major health burden in many countries. This review aimed to evaluate the efficacy of traditional herbal medicine (THM) combined with first-line platinum-based chemotherapy (PBCT) for the treatment of advanced NSCLC. Methods: From inception to April 2021, relevant studies were retrieved from 9 electronic databases. Randomized controlled trials (RCTs) comparing survival outcomes of THM + PBCT treatment with PBCT treatment in patients with advanced NSCLC were reviewed. The risk of bias was evaluated using the Cochrane Risk of Bias Tool. Overall survival, 1-year survival, progression-free survival or time to progression, tumor response rate, and adverse effects were analyzed. Results: Sixteen RCTs comprising 1445 patients were included. The meta-analysis indicated that THM + PBCT treatment, compared to PBCT alone, could improve overall survival (median survival ratio = 1.24, 95% confidence intervals [CI] [1.11, 1.39], P < .001), progression-free survival/time to progression (median survival ratio = 1.22, 95% CI [1.09, 1.37], P < .001), and the 1-year survival rate (risk ratio [RR] = 1.56, 95% CI [1.31, 1.86], P < .001). THM + PBCT also led to a higher tumor response rate (RR = 1.39, 95% CI [1.22, 1.59], P < .001) and lower incidence of thrombocytopenia (RR = 0.72, 95% CI [0.56, 0.92], P = .009) and nausea/vomiting (RR = 0.35, 95% CI [0.21, 0.57], P < .001), while there was no significant effect observed on leukopenia (RR = 0.68, 95% CI [0.34, 1.36], P = .27). Conclusion: THM, when used in combination with PBCT, might increase survival and the tumor response rate while decreasing the side effects caused by chemotherapy in patients with advanced NSCLC. However, considering the limited methodological qualities of the included trials, more rigorous RCTs are needed.Keywords
Funding Information
- Korea Health Industry Development Institute (HF20C0038)
This publication has 38 references indexed in Scilit:
- Traditional Herbal Medicine as Adjunctive Therapy for Nasopharyngeal CancerIntegrative Cancer Therapies, 2015
- Antitumor effect of traditional Chinese herbal medicines against lung cancerAnti-Cancer Drugs, 2014
- Cancer Prevention and TherapyIntegrative Cancer Therapies, 2013
- Integrated Chinese-Western therapy versus Western therapy alone on survival rate of patients with middle-late stage non-small-cell lung cancer middle-late stageJournal of Traditional Chinese Medicine, 2013
- The Efficacy of Chinese Herbal Medicine as an Adjunctive Therapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysisPLOS ONE, 2013
- The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A systematic review and meta-analysisComplementary Therapies in Medicine, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Chinese Herbal Medicine and Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Randomized Controlled TrialsIntegrative Cancer Therapies, 2005
- Placebo Effects in OncologyJNCI: Journal of the National Cancer Institute, 2003
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002